Crossmark

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Published Online: 2019-09-10

Published Print: 2019-12

Authors

Schmid, Sabine

Klingbiel, Dirk

Aebi, Stefan

Goldhirsch, Aron

Mamot, Christoph

Munzone, Elisabetta

Nolè, Franco

Oehlschlegel, Christian

Pagani, Olivia

Pestalozzi, Bernhard

Rochlitz, Christoph

Thürlimann, Beat

von Moos, Roger

Weder, Patrik

Zaman, Khalil

Ruhstaller, Thomas
Funding

Funding for this research was provided by:

Staatssekretariat für Bildung, Forschung und Innovation (SAKK)
License Information

Text and Data Mining valid from 2019-09-10

Version of Record valid from 2019-09-10
More Information

Article History

Received: 11 March 2019

Accepted: 29 August 2019

First Online: 10 September 2019

Ethics approval and consent to participate

: For the SAKK 22/99 main trial (publication Annals of Oncology 2017) patients provided written informed consent and the protocol was approved by local ethics committees (for a full list of all ethics committees and the corresponding institutes see Additional file : Table S1). The trial (NCT00004935) was conducted according to Good Clinical Practice, the Declaration of Helsinki and applicable regulatory requirements.

: The authors have declared the following competing interest:

Document is current